{{Rsnum
|rsid=9788969
|Gene=FAM38A
|Chromosome=16
|position=88745842
|Orientation=plus
|GMAF=0.4564
|Gene_s=PIEZO1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 12.4 | 50.4 | 37.2
| HCB | 48.2 | 41.6 | 10.2
| JPT | 38.1 | 53.1 | 8.8
| YRI | 53.7 | 40.1 | 6.1
| ASW | 38.6 | 47.4 | 14.0
| CHB | 48.2 | 41.6 | 10.2
| CHD | 50.0 | 42.6 | 7.4
| GIH | 14.0 | 47.0 | 39.0
| LWK | 34.9 | 48.6 | 16.5
| MEX | 22.4 | 55.2 | 22.4
| MKK | 43.6 | 40.4 | 16.0
| TSI | 14.7 | 54.9 | 30.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9788969
|Name_s=
|Gene_s=FAM38A
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109383
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9788969
|overall_frequency_n=68
|overall_frequency_d=128
|overall_frequency=0.53125
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=63
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}